On CAR-Ts, decentralized in-house models, and the hospital exception. Routes for sustainable access to innovative therapies
{{output}}
Chimeric Antigen Receptor T cells, or CAR-Ts, are a novel class of gene and cell 'one-shot' therapies based upon collecting, reprogramming, and using patients' own immune cells to treat their cancer. The article discusses the status, prospects, and some releva... ...
